Journal Des Maladies Vasculaires最新文献

{"title":"Polymorphisms and expression levels of TNP2, SYCP3, and AZFa genes in patients with azoospermia.","authors":"Mohammad Ismael Ibrahim Jebur, Narges Dastmalchi, Parisa Banamolaei, Reza Safaralizadeh","doi":"10.5653/cerm.2023.06219","DOIUrl":"10.5653/cerm.2023.06219","url":null,"abstract":"<p><strong>Objective: </strong>Azoospermia (the total absence of sperm in the ejaculate) affects approximately 10% of infertile males. Despite diagnostic advances, azoospermia remains the most challenging issue associated with infertility treatment. Our study evaluated transition nuclear protein 2 (TNP2) and synaptonemal complex protein 3 (SYCP3) polymorphisms, azoospermia factor a (AZFa) microdeletion, and gene expression levels in 100 patients with azoospermia.</p><p><strong>Methods: </strong>We investigated a TNP2 single-nucleotide polymorphism through polymerase chain reaction (PCR) restriction fragment length polymorphism analysis using a particular endonuclease. An allele-specific PCR assay for SYCP3 was performed utilizing two forward primers and a common reverse primer in two PCR reactions. Based on the European Academy of Andrology guidelines, AZFa microdeletions were evaluated by multiplex PCR. TNP2, SYCP3, and the AZFa region main gene (DEAD-box helicase 3 and Y-linked [DDX3Y]) expression levels were assessed via quantitative PCR, and receiver operating characteristic curve analysis was used to determine the diagnostic capability of these genes.</p><p><strong>Results: </strong>The TNP2 genotyping and allelic frequency in infertile males did not differ significantly from fertile volunteers. In participants with azoospermia, the allelic frequency of the SYCP3 mutant allele (C allele) was significantly altered. Deletion of sY84 and sY86 was discovered in patients with azoospermia and oligozoospermia. Moreover, SYCP3 and DDX3Y showed decreased expression levels in the azoospermia group, and they exhibited potential as biomarkers for diagnosing azoospermia (area under the curve, 0.722 and 0.720, respectively).</p><p><strong>Conclusion: </strong>These results suggest that reduced SYCP3 and DDX3Y mRNA expression profiles in testicular tissue are associated with a higher likelihood of retrieving spermatozoa in individuals with azoospermia. The homozygous genotype TT of the SYCP3 polymorphism was significantly associated with azoospermia.</p>","PeriodicalId":50262,"journal":{"name":"Journal Des Maladies Vasculaires","volume":"40 1","pages":"253-261"},"PeriodicalIF":1.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10711250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76594669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cold snare polypectomy for duodenal adenomas in familial adenomatous polyposis: a prospective international cohort study.","authors":"Arthur S Aelvoet, John G Karstensen, Barbara A J Bastiaansen, Monique E van Leerdam, Francesc Balaguer, Michal Kaminski, Roel Hompes, Patrick M M Bossuyt, Luigi Ricciardiello, Andrew Latchford, Rodrigo Jover, Maria Daca-Alvarez, Maria Pellisé, Evelien Dekker","doi":"10.1055/a-2165-7436","DOIUrl":"10.1055/a-2165-7436","url":null,"abstract":"<p><p><b>Background and study aims</b> In patients with familial adenomatous polyposis (FAP), endoscopic resection of duodenal adenomas is commonly performed to prevent cancer and prevent or defer duodenal surgery. However, based on studies using different resection techniques, adverse events (AEs) of polypectomy in the duodenum can be significant. We hypothesized that cold snare polypectomy (CSP) is a safe technique for duodenal adenomas in FAP and evaluated its outcomes in our centers. <b>Patients and methods</b> We performed a prospective international cohort study including FAP patients who underwent CSP for one or more superficial non-ampullary duodenal adenomas of any size between 2020 and 2022. At that time, this technique was common practice in our centers for superficial duodenal adenomas. The primary outcome was the occurrence of intraprocedural and post-procedural AEs. <b>Results</b> In total, 133 CSPs were performed in 39 patients with FAP (1-18 per session). Median adenoma size was 10 mm (interquartile range 8-15 mm), ranging from 5 to 40 mm; 27 adenomas were ≥20 mm (20%). Of the 133 polypectomies, 109 (82%) were performed after submucosal injection. Sixty-one adenomas (46%) were resected en bloc and 72 (54%) piecemeal. Macroscopic radical resection was achieved for 129 polypectomies (97%). Deep mural injury type II occurred in three polyps (2%) with no delayed perforation after prophylactic clipping. There were no clinically significant bleeds, perforations or other post-procedural AEs. Histopathology showed low-grade dysplasia in all 133 adenomas. <b>Conclusions</b> CSP for (multiple) superficial non-ampullary duodenal adenomas in FAP seems feasible and safe. Long-term prospective research is needed to evaluate whether protocolized duodenal polypectomies prevent cancer and surgery.</p>","PeriodicalId":50262,"journal":{"name":"Journal Des Maladies Vasculaires","volume":"40 1","pages":"E1056-E1062"},"PeriodicalIF":2.6,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76594885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traitement de l’artérite jambière : les frontières de la chirurgie vasculaire sont repoussées","authors":"C. Caradu,&nbsp;A.S. Battut,&nbsp;C. Gonthier,&nbsp;D. Midy,&nbsp;E. Ducasse","doi":"10.1016/j.jmv.2016.07.006","DOIUrl":"10.1016/j.jmv.2016.07.006","url":null,"abstract":"<div><p>Un tiers des patients en ischémie critique chronique (ICC) présente une artérite jambière nécessitant la restauration d’un flux direct dans le pied. Cependant, beaucoup sont inéligibles à une chirurgie ouverte. Les objectifs premiers sont devenus le soulagement de la douleur et le sauvetage de membre plus que la perméabilité. Le concept d’angiosome aide à déterminer l’artère cible à traiter en priorité. L’approche endovasculaire a permis de diminuer significativement la morbi-mortalité comparée aux pontages distaux ; tandis que les techniques subintimales, rétrogrades, trans-collatérales et « <em>loop</em> » repoussent les limites de la chirurgie ouverte en permettant de réouvrir l’arche plantaire et d’améliorer ainsi le lit d’aval. Les phénomènes de resténose précoce après angioplastie ont pu être améliorés par l’utilisation de ballons actifs enduits de – limus et de stents sertis sur ballon en cas de dissection limitant le flux ou de « <em>recoil</em> » permettant ainsi d’augmenter les taux de sauvetage de membre. Par ailleurs, des stents actifs ont été proposés et permettent une diminution des taux de réintervention et de resténose intra-stent dans les lésions courtes ; cependant, les résultats sur les taux d’amputation ou de survie restent limités. La préparation des vaisseaux est un point primordial pour surmonter certaines limitations actuelles avec notamment l’athérectomie qui augmente les taux de succès technique et diminue les taux de resténose, notamment dans les lésions calcifiées, les occlusions totales chroniques et les resténoses. Ces avancées techniques dans la revascularisation endovasculaire distale ont révolutionné le sauvetage de membre et supportent l’intérêt d’une prise en charge endovasculaire première dans le traitement de l’ICC.</p></div><div><p>One third of patients with critical limb ischemia (CLI) has below the knee lesions and requires a restoration of direct blood flow into the foot. However, many of these patients are ineligible for open surgery. The primary goals thus become pain relief and limb salvage over patency. The angiosome concept helps determine the target artery to treat in priority. The endovascular approach has decreased morbidity and mortality rates compared to distal bypass surgery; while subintimal retrograde, trans-collateral and loop techniques push the limits of open surgery by reopening the plantar arch, thereby improving run-off. Early restenosis phenomena after angioplasty have been improved by the use of – limus drug eluting balloons and balloon expandable stents in case of flow limiting dissection or recoil with increased limb salvage rates. Moreover, drug-eluting stents have been proposed, and allow a reduction in reintervention and in-stent restenosis rates in short lesions; however, results on amputation rates or survival are limited. Vessel preparation is a key to overcoming some current limitations, including atherectomy, which increases technical success rates and reduces resteno","PeriodicalId":50262,"journal":{"name":"Journal Des Maladies Vasculaires","volume":"41 6","pages":"Pages 378-382"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jmv.2016.07.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34417422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conséquences économiques du suivi biologique et des complications médicales en lien avec l’utilisation des anticoagulants injectables en France","authors":"P. Paubel ,&nbsp;M. Cousin ,&nbsp;C. Amar ,&nbsp;J. Gourmelen ,&nbsp;C. Fabron ,&nbsp;B. Detournay","doi":"10.1016/j.jmv.2016.10.001","DOIUrl":"10.1016/j.jmv.2016.10.001","url":null,"abstract":"<div><h3>Objectif</h3><p>Déterminer la fréquence du suivi plaquettaire et les risques hémorragiques associés à l’usage des anticoagulants injectables en vie réelle et estimer les coûts associés.</p></div><div><h3>Méthode</h3><p>Une analyse des données 2013 de l’échantillon généraliste des bénéficiaires a été réalisée pour identifier les dosages plaquettaires effectués sur les périodes d’exposition aux anticoagulants injectables et les interruptions thérapeutiques du fait d’une thrombopénie ou d’une transfusion. Ces évènements ont été valorisés et un différentiel de coût établi.</p></div><div><h3>Résultats</h3><p>L’étude a porté sur 15 985 patients adultes représentant 12 264 mois d’exposition aux anticoagulants injectables ; 2,8 % des séquences concernaient une héparine non fractionnée, 86,9 % une héparine de bas poids moléculaire et 13,1 % le fondaparinux. Les patients sous héparine non fractionnée étaient plus âgés (77 vs 57 et 59 ans) avec des durées de traitement supérieures (32,6 vs 25,1 et 21<!--> <!-->jours). Le nombre mensuel moyen de dosages plaquettaires était, après ajustement, 1,36 fois inférieur chez les patients traités par fondaparinux par rapport aux héparines de bas poids moléculaire (<em>p</em> <!-->&lt;<!--> <!-->0,0001). Aucun écart n’était constaté sur la fréquence des accidents hémorragiques avec transfusion (<em>p</em> <!-->=<!--> <!-->0,76) ou des thrombopénies hospitalisées (<em>p</em> <!-->=<!--> <!-->0,82) entre héparine de bas poids moléculaire et fondaparinux. Extrapolé au plan national, le suivi biologique représente 21,6 M€ et 0,9 M€ respectivement pour ces deux classes.</p></div><div><h3>Conclusion</h3><p>Les patients sous fondaparinux effectuent significativement moins de dosages plaquettaires que les patients sous héparines de bas poids moléculaire sans risque hémorragique supplémentaire. Cet aspect doit être pris en compte dans l’évaluation des coûts de ces traitements.</p></div><div><h3>Aim</h3><p>To assess the frequency of platelet monitoring and bleeding risks associated with the use of injectable anticoagulants in a real life setting and to estimate the associated costs.</p></div><div><h3>Method</h3><p>An analysis of the 2013 data from a random sample of ≈<!--> <!-->600,000 patients registered in the French National Health Insurances reimbursement database was conducted to identify platelet counts performed during injectable anticoagulants exposure period and treatment interruptions due to heparin-induced thrombocytopenia or transfusion. Events were then valued to establish associated costs.</p></div><div><h3>Results</h3><p>Overall 15,985 adult patients representing a cumulated injectable anticoagulants exposure time of 12,264 months were selected. Treatment sequences involved unfractionated heparin (2.8%), low molecular weight heparin (86.9%), and fondaparinux (13.1%). Patients treated with unfractionated heparin were older (77 vs. 57 and 59 years) with longer treatment duration (32.6 vs. 25.1 and 21 days).","PeriodicalId":50262,"journal":{"name":"Journal Des Maladies Vasculaires","volume":"41 6","pages":"Pages 371-377"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jmv.2016.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54563705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus anticoagulant-hypoprothrombinemia syndrome presenting with co-existing cerebral venous thrombosis and subdural hemorrhage","authors":"N. Bel Feki ,&nbsp;S. Zayet ,&nbsp;I. Ben Ghorbel ,&nbsp;M.-H. Houman","doi":"10.1016/j.jmv.2016.07.003","DOIUrl":"10.1016/j.jmv.2016.07.003","url":null,"abstract":"<div><p>The lupus anticoagulant-hypoprothrombinemia syndrome (LA-HPS) – the association of acquired factor II deficiency and lupus anticoagulant – is a rare disease that may cause a predisposition not only to thrombosis but also to severe bleeding. We are reporting on a 36-year-old female patient presenting with co-existing cerebral venous thrombosis and subdural hemorrhage. The coagulation screening showed a prolonged prothrombin time (PT), activated partial thromboplastin time (aPTT), and a normal fibrinogen level and platelet count. Evaluation of the clotting factors revealed decreased levels of factors II (37%). Factors V, VIII, IX and XI were normal. Lupus anticoagulant (LA) was demonstrated by the Dilute Russell's Viper Venom Test (DRVVT). Immunological work-up was positive for IgG type anticardiolipines antibodies (aCL). Successful management consisted first of oral prednisone (60<!--> <!-->mg/d). Thus, anticoagulation was introduced once factor II had stabilized.</p></div><div><p>Le syndrome lupus anticoagulant-hypoprothrombinémie est une maladie rare qui associe un déficit acquis en facteur II et la présence d’un lupus anticoagulant circulant responsable de survenue de thrombose et d’hémorragie parfois sévères. Nous rapportons l’observation d’une patiente de 36<!--> <!-->ans présentant une thrombose veineuse cérébrale et une hémorragie sous-durale d’une façon simultanée. Le bilan d’hémostase montrait un temps de prothrombine bas et un temps de céphaline activée allongé. Le taux de fibrinogène et la numération des plaquettes étaient normaux. Le dosage des facteurs de coagulation ont révélé une diminution du facteur II (37 %). Les facteurs V, VIII, IX et XI étaient normaux. Le temps de venin de vipère Russell dilué (dRVVT) a permis de mettre en évidence un anticoagulant circulant de type lupus. Les anticorps anticardiolipines étaient positifs de type IgG. Le traitement consistait d’abord en une corticothérapie orale (60<!--> <!-->mg/jour) puis une introduction dans un deuxième temps d’une anticoagulation après normalisation du facteur II.</p></div>","PeriodicalId":50262,"journal":{"name":"Journal Des Maladies Vasculaires","volume":"41 6","pages":"Pages 403-406"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jmv.2016.07.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54563599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paraneoplastic systemic sclerosis: About 3 cases and review of literature","authors":"J.-B. Monfort,&nbsp;I. Lazareth,&nbsp;P. Priollet","doi":"10.1016/j.jmv.2016.07.001","DOIUrl":"10.1016/j.jmv.2016.07.001","url":null,"abstract":"<div><h3>Objective</h3><p>Association between cancer and systemic sclerosis (SSc) has been described. However, paraneoplastic SSc is not well known. The aim of this article is to describe cases of paraneoplastic systemic sclerosis and to compare them to other cases of the literature, to find characteristics that can make suspect a paraneoplastic mechanism when SSc is diagnosed.</p></div><div><h3>Methods</h3><p>We retrospectively analyzed patients, in our department who, over the last 15 years, presented with Raynaud's phenomenon with a diagnosis of SSc (including cancer during the period of SSc). Treatment of cancer had to be concomitted with an improvement of sclerosis and/or negativation of antinuclear antibodies. Review analysis of other cases was made with Pubmed.</p></div><div><h3>Results</h3><p>Three patients responded to the criteria. Two of them had an ovarian cancer with peritoneal carcinomatosis and a concomitted SSc. One had a colon cancer with an ovarian metastasis diagnosed 1 year before SSc. None of them had anti-ENA antibody. One had a normal capillaroscopy. After treatment of cancer, all of them had an improvement of sclerosis and a negativation of antinuclear antibodies.</p></div><div><h3>Conclusion</h3><p>We believe that physicians should be aware of paraneoplastic SSc when presentation of SSc is atypical: no anti-ENA (anti-SCl70 or anti-centromere) or normal capillaroscopy, in particular gynecologic cancer in women.</p></div><div><h3>Objectif</h3><p>L’association entre le cancer et la sclérodermie systémique (SSc) a déjà été décrite. Cependant, la SSc paranéoplasique est mal connue. L’objectif de cet article était de décrire des cas de SSc paranéoplasiques, de les comparer à ceux décrits dans la littérature et de mettre en évidence des caractéristiques pouvant faire évoquer une origine paranéoplasique lors d’une SSc.</p></div><div><h3>Méthodes</h3><p>Nous avons analysé de façon rétrospective les patients de notre service s’étant présentés pour un phénomène de Raynaud avec un diagnostic de SSc et ayant eu un cancer concomitant. Le traitement du cancer devait amener à une amélioration de la sclérose et/ou à la négativation des facteurs antinucléaires. La revue de la littérature a été effectuée à partir de PubMed.</p></div><div><h3>Résultats</h3><p>Trois patientes répondaient à ces critères. Deux d’entre elles avaient un cancer des ovaires avec une carcinose péritonéale et une SSC concomitante. Une patiente avait un cancer du côlon avec des métastases ovariennes diagnostiquées un an avant la SSc. Toutes avaient des anti-ECT négatifs. Une patiente avait une capillaroscopie normale. Après le traitement du cancer, les 3 patientes avaient une amélioration de la sclérose cutanée et une négativation des FAN.</p></div><div><h3>Conclusion</h3><p>Il faut donc évoquer une SSc paranéoplasique lorsque la présentation de la SSC est atypique : absence d’anti-ECT (anti-Scl70 ou anti-centromère) ou une capillaroscopie normale, en particulier en c","PeriodicalId":50262,"journal":{"name":"Journal Des Maladies Vasculaires","volume":"41 6","pages":"Pages 365-370"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jmv.2016.07.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54563566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal function and venous thromboembolic diseases","authors":"N. Janus ,&nbsp;I. Mahé ,&nbsp;V. Launay-Vacher ,&nbsp;J.-P. Laroche ,&nbsp;G. Deray","doi":"10.1016/j.jmv.2016.09.001","DOIUrl":"10.1016/j.jmv.2016.09.001","url":null,"abstract":"<div><p><span>Anticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal </span>pulmonary embolism<span>. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agents in CKD patients because of the pharmacokinetic modifications of these drugs in this population. These modifications may lead to overdosage and dose-related side effects, such as bleeding. It is therefore necessary to screen VTE patients for CKD and to modify the doses of anticoagulants, if necessary.</span></p></div><div><p>Les anticoagulants ont été approuvés par les autorités européennes dans l’indication de traitement et de prévention des maladies thromboemboliques veineuses (MTEV). Cependant, l’insuffisance rénale chronique (IRC) est : (1) fréquente chez les patients présentant une MTEV ; et (2) étroitement liée à l’apparition des MTEV. Ainsi, il existe un nombre croissant de patients présentant une IRC et une MTEV et de plus en plus de médecins et de pharmaciens sont confrontés à la question de la gestion des anticoagulants chez ces patients à cause des modifications de la pharmacocinétique des anticoagulants. Ces modifications peuvent conduire à des surdosages et des effets indésirables dose-dépendants, comme des hémorragies. Il est donc nécessaire de dépister l’IRC chez ces patients et d’adapter la posologie des anticoagulants au besoin.</p></div>","PeriodicalId":50262,"journal":{"name":"Journal Des Maladies Vasculaires","volume":"41 6","pages":"Pages 389-395"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jmv.2016.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54563674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immediate and transient faintness following a course of foam sclerotherapy treatment for saphenous vein incompetence in an elderly patient","authors":"D. Rastel","doi":"10.1016/j.jmv.2016.09.002","DOIUrl":"10.1016/j.jmv.2016.09.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Adverse effects of sclerotherapy are rare. They are divided into two categories: immediate and delayed. Immediate adverse effects are mainly represented by visual disturbances. We are reporting the case of an immediate transient faintness following two sessions of foam sclerotherapy.</p></div><div><h3>Observation</h3><p>An 80-year-old active female with superficial chronic venous disorder and no significant medical or surgical backgrounds experienced two similar immediate general adverse events following two sessions of sclerotherapy from a total of five. Adverse reactions included faintness, associated with headache but without visual disturbance, lasting ten minutes with full short and long-term recoveries. The common factor between those two sessions was the injection of a higher volume of sclerosing agent compared to the other sessions, 5<!--> <!-->mL of which was foam.</p></div><div><h3>Conclusion</h3><p>Age is not a contraindication of foam sclerotherapy. Nevertheless, we must proceed with caution even when moderate quantities of foam are required.</p></div><div><h3>Introduction</h3><p>Les effets indésirables immédiats de la sclérothérapie sont en majorité des troubles visuels et exceptionnellement des malaises. Nous rapportons ici le cas d’une patiente ayant présenté deux épisodes de malaises au décours de deux séances de sclérothérapie à la mousse.</p></div><div><h3>Observation</h3><p>Une femme de 80 ans, active, avec indication de sclérothérapie pour insuffisance veineuse superficielle saphène variqueuse et symptomatique bilatérale a présenté lors de deux séances de sclérothérapie sur une série de cinq, deux malaises brefs similaires sans perte de connaissance et sans trouble visuel, à type de faiblesse générale, engourdissement des deux membres supérieurs, céphalées. Les facteurs de risque cardiovasculaire étaient limités à une hypertension artérielle contrôlée et une dyslipidémie modérée non traitée. La récupération sans séquelle survenait en quelques minutes. Lors de ces deux malaises, le seul point commun fut une injection d’un volume plus élevée d’agent sclérosant (5<!--> <!-->mL de mousse) que lors des autres sessions de sclérothérapie à la mousse.</p></div><div><h3>Conclusion</h3><p>Les effets secondaires inhabituels de la sclérothérapie à la mousse ne sont pas l’apanage des personnes âgées. La technique étant, à ce jour, considérée comme ne nécessitant pas de précaution particulière dans le grand âge. Cependant, l’information au patient se doit d’être exhaustive d’où l’intérêt de ce cas clinique.</p></div>","PeriodicalId":50262,"journal":{"name":"Journal Des Maladies Vasculaires","volume":"41 6","pages":"Pages 412-415"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jmv.2016.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54563685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Axillary artery injury from a closed humeral neck fracture: A case report","authors":"H. Naouli,&nbsp;B. Benfor,&nbsp;H. Jiber,&nbsp;A. Bouarhroum","doi":"10.1016/j.jmv.2016.07.002","DOIUrl":"10.1016/j.jmv.2016.07.002","url":null,"abstract":"<div><p>Axillary artery injury from humeral neck fracture is an uncommon event. Vascular damage due to these injuries may threaten limb loss. In some cases, the signs of ischemia may not be evident just after the injury and may only appear later on. Therefore, a high index of suspicion is essential. It is important to bear this association in mind, so as to make an early diagnosis and avoid serious complications. We are describing the case of a young patient involved in a motor vehicle crash with an axillary artery trauma due to the surgical neck of humerus fracture. The patient underwent a basilic vein grafting, the postoperative course was good.</p></div><div><p>Les traumatismes de l’artère axillaire secondaires à une fracture du col chirurgical de l’humérus est une entité pathologique rare. Cette lésion vasculaire peut compromettre la viabilité du membre. Les signes d’ischémie peuvent manquer dans certains cas, et n’apparaissent que tardivement. Un diagnostic précoce reste donc primordial afin de prévenir une ischémie irréversible et éviter ainsi une amputation de membre dramatique. Nous rapportons l’observation d’un jeune admis pour une lésion de l’artère axillaire suite à une fracture fermée du col chirurgical de l’humérus. Le patient a bénéficié d’une réparation de l’artère axillaire par interposition d’un greffon veineux basilique, les suites opératoires ont été simples.</p></div>","PeriodicalId":50262,"journal":{"name":"Journal Des Maladies Vasculaires","volume":"41 6","pages":"Pages 407-411"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jmv.2016.07.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54563585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antivitaminiques K, anticoagulants oraux directs : où est la vérité ?","authors":"J.-P. Laroche ,&nbsp;J.-F. Schved","doi":"10.1016/j.jmv.2016.10.002","DOIUrl":"10.1016/j.jmv.2016.10.002","url":null,"abstract":"<div><p>Les antivitamiques K (AVK) et les anticoagulants oraux directs (AOD) sont aujourd’hui en concurrence. Les arguments développés autour des AOD amènent à se poser la question de savoir si les AVK doivent totalement disparaître au profit des AOD, ou du moins ne garder que les niches laissées par les contre-indications des AOD<em>.</em> Les questions que suscite l’arrivée des AOD sont nombreuses. Le but de cette mise au point est de tenter d’apporter une vision objective. Il ne s’agit pas de dénigrer l’un ou l’autre mais de pouvoir choisir entre ces deux familles d’anticoagulants afin que tout prescripteur puisse utiliser l’un ou l’autre en toute connaissance de cause et en toute sécurité.</p></div><div><p>Vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) are now in competition. The companies are trying to replace VKA by DOACs, totally or at least greatly VKA should VKA disappear in favor of DOACs? There are still many questions about DOACs. The purpose of this article is to make a well-considered decision in this area. The aim is not to denigrate one or the other but to share things between these two families of anticoagulants. Physicians using these drugs must have a full knowledge about compared efficacy and safety. We feel necessary to increase distance between effective results of the clinical trials and industrial communication around DOACs.</p></div>","PeriodicalId":50262,"journal":{"name":"Journal Des Maladies Vasculaires","volume":"41 6","pages":"Pages 383-388"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jmv.2016.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54563734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}